[HTML][HTML] Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
G Janani, A Girigoswami, K Girigoswami - ADMET and DMPK, 2023 - hrcak.srce.hr
Background and purpose The reciprocal translocation of the ABL gene from chromosome 9
to chromosome 22 near the BCR gene gives rise to chronic myelogenous leukemia (CML) …
to chromosome 22 near the BCR gene gives rise to chronic myelogenous leukemia (CML) …
Lifelong TKI therapy: how to manage cardiovascular and other risks
MJ Mauro - Hematology, 2021 - ashpublications.org
Beginning with imatinib and now spanning 6 oral, highly active, and mostly safe agents, the
development of specific targeted therapy for patients with chronic myeloid leukemia (CML) …
development of specific targeted therapy for patients with chronic myeloid leukemia (CML) …
Development of BCR-ABL1 transgenic zebrafish model reproducing chronic myeloid leukemia (CML) like-disease and providing a new insight into CML mechanisms
Zebrafish has proven to be a versatile and reliable experimental in vivo tool to study human
hematopoiesis and model hematological malignancies. Transgenic technologies enable the …
hematopoiesis and model hematological malignancies. Transgenic technologies enable the …
[HTML][HTML] Management of chronic myeloid leukemia presenting with isolated thrombocytosis and complex Philadelphia chromosome: a case report
L Gao, M Ren, Z Tian, Z Peng, G Shi, Z Yuan - Medicine, 2021 - journals.lww.com
Interventions: The patients received continuously oral imatinib mesylate tablets (400 mg)
once a day. Outcomes: After treatment with imatinib for 3 months, the BCR/ABL IS was less …
once a day. Outcomes: After treatment with imatinib for 3 months, the BCR/ABL IS was less …
Advances in Nanotechnology for Enhanced Leukemia Therapy: A Systematic Review of In Vivo Studies
AM Hosseini, S Dianaty, S Shahhosseini… - Journal of Lab Animal …, 2023 - jlar.rovedar.com
Introduction: Leukemia, a heterogeneous group of blood cancers, can present a significant
clinical challenge due to its varying subtypes and complexity. The application of …
clinical challenge due to its varying subtypes and complexity. The application of …
Két myeloproliferativ betegség egy betegben–klónok együttélése és vetélkedése
S Fekete, J Reichardt, A Kozma, K Kapócs… - Orvosi …, 2022 - akjournals.com
A myeloproliferativ betegségeket genetikai hátterük alapján Philadelphia-kromoszóma-
pozitív krónikus myeloid leukaemia, illetve Philadelphia-kromoszóma-negatív klasszikus …
pozitív krónikus myeloid leukaemia, illetve Philadelphia-kromoszóma-negatív klasszikus …
Case report of a patient with chronic myeloid leukemia, BCR::ABL1 positive presented with isolated thrombocytosis and an uncommon JAK2 alteration detected in …
AL Gray, EA Wappler-Guzzetta, J Wang… - Journal of …, 2022 - Springer
Chronic myeloid leukemia (CML) is a common myeloproliferative neoplasm (MPN).
However, CML presenting with isolated thrombocytosis and lacking all the typical features of …
However, CML presenting with isolated thrombocytosis and lacking all the typical features of …